The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases

ISSN: 2212-4055 (Online)
ISSN: 1871-5281 (Print)


Volume 13, 6 Issues, 2014


Download PDF Flyer




Inflammation & Allergy - Drug Targets

Formerly: 'Current Drug Targets - Inflammation & Allergy

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448
Germany


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases

Author(s): Eric Toussirot and Matthieu Bereau

Affiliation: University Hospital of Besançon, Clinical Investigation Center for Biotherapy INSERM CIC-1431, Place St Jacques, 25000 Besançon, France.

Abstract

Biological agents such as monoclonal antibodies and soluble cytokine receptors have taken on an expanding role in the treatment of chronic immune mediated diseases. Progressive multifocal leukoencephalopathy (PML) is a rare central neurological disease caused by JC virus infection that has been described in the setting of conditions with severe impairment of immune surveillance, such as haematological malignancies, stem cell or solid organ transplantation and AIDS. This serious demyelinating disease has recently been described in patients receiving monoclonal antibodies for chronic inflammatory diseases such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus or psoriasis. We review here the disease of PML, the different biological agents used in chronic inflammatory diseases that are associated with an increased risk of PML (natalizumab, rituximab, efalizumab and alemtuzumab), and the potential mechanisms that may explain the development of PML. Based on current knowledge of the biology of the JC virus and on the mechanisms of action of these biological agents, we discuss currently available tools that may be helpful in evaluating the risk of PML in this patient population.

Keywords: JC virus, progressive multifocal leukoencephalopathy, monoclonal antibodies, natalizumab, rituximab.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 13
Issue Number: 2
First Page: 121
Last Page: 127
Page Count: 7
DOI: 10.2174/1871528113666140224103712
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science